Dalane Kitzman to Spironolactone
This is a "connection" page, showing publications Dalane Kitzman has written about Spironolactone.
Connection Strength
1.858
-
Kitzman DW, Upadhya B. Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2019 12; 7(12):1029-1031.
Score: 0.724
-
Upadhya B, Hundley WG, Brubaker PH, Morgan TM, Stewart KP, Kitzman DW. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. J Am Geriatr Soc. 2017 Nov; 65(11):2374-2382.
Score: 0.607
-
Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 2009 Mar-Apr; 15(2):68-74.
Score: 0.344
-
Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2018 06; 5(3):257-266.
Score: 0.159
-
Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr; 32(7):820-8.
Score: 0.024